Celldex Q2 net loss widens on higher R&D, G&A expenses

Celldex Therapeutics

06/08/2026 21:26

Overview
US biotech firm's Q2 net loss and loss per share both beat analyst expectations
No material revenue recognized in Q2, down from prior year due to fewer R&D agreements
R&D and G&A expenses rose on higher clinical trial and commercial planning costs

Outlook
Celldex expects topline Phase 3 barzolvolimab CSU data in Sept/Oct 2026, BLA filing in 2027
Company sees topline Phase 2 atopic dermatitis data in late 2026
Celldex says cash, equivalents and securities sufficient to fund operations through 2028

Result Drivers
CLINICAL TRIAL EXPANSION - Co said higher R&D expenses were driven by increased barzolvolimab clinical trial and manufacturing costs
COMMERCIAL PLANNING COSTS - Co said higher G&A expenses were due to increased barzolvolimab commercial planning
PROGRAM DISCONTINUATION - Co discontinued Phase 2 prurigo nodularis study after failing to meet endpoints; mast cells may not be key driver

Company press release: ID:nGNX8vzKfq

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$22,000
 
Q2 Loss Per Share
Beat
$0.94
$1.06 (14 Analysts)
Q2 Net Loss
Beat
$73.50 mln
$81.21 mln (11 Analysts)
Q2 Operating Expenses
 
$80.65 mln
 
Q2 Operating Income
 
-$80.62 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Celldex Therapeutics, Inc. is $56.00, about 36.4% above its August 5 closing price of $41.06

Reuters Recommended Reads
Aug 4 - Spyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026
Aug 6 - Compass Therapeutics Q2 net loss widens on higher R&D and G&A costs
Aug 4 - Dianthus Therapeutics Q2 net loss widens as R&D costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)